Therapeutic Targeting of the Proinflammatory IL-6-JAK/STAT Signalling Pathways Responsible for Vascular Restenosis in Type 2 Diabetes Mellitus

<div>IL-6 classical and trans-signalling. (a) In classical signalling, IL-6 binds to a membrane-bound IL-6 receptor molecule in addition to two flanking gp130 molecules. Signalling through this pathway mediates anti-inflammatory signalling and is prevalent in blood cells and hepatocytes. (b) Trans-signalling occurs on the majority of other cell types, including cells of the vascular walls. Here, a soluble IL-6 receptor molecule is utilised in combination with two gp130 molecules. This truncated, soluble IL-6 receptor is responsible for many of the proinflammatory actions of IL-6 in disease.</div>

Cardiology Research and Practice

fig3

Figure 3

Figure 3: Therapeutic Targeting of the Proinflammatory IL-6-JAK/STAT Signalling Pathways Responsible for Vascular Restenosis in Type 2 Diabetes Mellitus 

Figure 3 | Therapeutic Targeting of the Proinflammatory IL-6-JAK/STAT Signalling Pathways Responsible for Vascular Restenosis in Type 2 Diabetes Mellitus 